( 图片来源：《澳华财经在线》) 【财经要闻及评论】 NAB澳洲国民银行预计澳储行将在2月和5月加息 澳洲国民银行（NAB）目前预测，澳储行（RBA）将在2026年2月和5月分别加息。 这是澳洲四大行中第二家预测2026年将加息的银行。 随着控制权顺利移交给亿万富豪Mathieson家族和美国Bally's公司，Star已度过生死一线，但仍面临因历 史洗钱行为而可能被澳洲交易报告和分析中心处以高额罚款，以及难以获得长期贷款等方面的挑战和威 胁。 最近上任的董事局主席Bruce Mathieson Jnr将接管McCann行政职务，直至找到继任者。 NAB首席经济学家Sally Auld表示，目前本地经济已处于趋势增长水平，私营部门最终需求也比澳储行 预期的更为强劲。 NAB商业调查显示，国内各行业产能利用率普遍有所提高，并且接受调查的企业报告称近几个月利润 率方面的压力有所减轻。 "澳储行在政策立场上表现出不确定性，不再认为3.6%的政策利率'……略显偏紧'。" 通胀压力持续存在情况下，NAB认为澳储行将在2026年上半年对货币政策进行适度调整。 "救火CEO"携1600万澳元天价薪酬功成身退 赌场巨头Sta ...

We recently published 7 Best ASX Stocks to Buy Right Now.  Radiopharm Theranostics Limited (NASDAQ:RADX) is one of the best ASX stocks. Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B. Riley lowered its share price target for the firm to $13 from $15 and kept a Buy rating for the shares on November 26th. As part of its coverage, the research firm discussed Radiopharm Theranostics Limited (NASDAQ:RAD ...

Radiopharm Theranostics Limited (NASDAQ:RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro.On Monday, Radiopharm Theranostics shared interim data from the first twelve patients in its U.S. Phase 2b imaging trial of RAD 101 in brain metastases.RAD 101 is a small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain ...

Core Insights - The interim analysis of RAD 101 shows that 92% of evaluable patients achieved concordance with MRI imaging, indicating significant tumor uptake in brain metastases [1][2] - The company plans to initiate a pivotal study by the end of 2026, bolstered by the positive interim data from the Phase 2b trial [3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [1][10] - The company is listed on ASX (RAD) and NASDAQ (RADX) and has a pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors [10] Clinical Trial Details - The Phase 2b clinical trial is evaluating the diagnostic performance of RAD 101 in 30 individuals with confirmed recurrent brain metastases from solid tumors [8] - The primary objective is to assess concordance between RAD 101 positive lesions and those seen in conventional MRI imaging [8] Market Opportunity - The U.S. market opportunity for RAD 101 is estimated to exceed $500 million annually, positioning it among the top three imaging agents in the market [3] - Over 300,000 patients are diagnosed with brain metastases annually in the U.S., highlighting a significant patient population for RAD 101 [4][3] Technology and Innovation - RAD 101 is a novel imaging agent targeting fatty acid synthase (FASN), which is overexpressed in many solid tumors, including brain metastases [9] - The integration of RAD 101 PET with standard MRI could enhance patient management and treatment decisions for brain metastases [3]

Core Viewpoint - The article discusses the best ASX stocks to buy, highlighting the impact of interest rate trends in Australia and the performance of specific biotechnology companies [1][2][3]. Interest Rate Trends - The Reserve Bank of Australia (RBA) Governor Michele Bullock indicated that there are no foreseeable interest rate cuts, suggesting a potential for rate hikes in the future [2][3]. - Bullock's comments surprised many, as she clearly signaled that further interest rate cuts are off the table, preparing the market for a possible tightening bias [3]. Company Highlights Immuron Limited (NASDAQ:IMRN) - Immuron Limited is a biotechnology company focused on preventing diarrhea and developing similar medicines [8]. - The company faced a significant setback with a 25.8% drop in share price after a clinical trial for its ETEC hyperimmune bovine colostrum product failed to meet its primary endpoint [8]. - Despite the setback, the FDA cleared Immuron's IMM-529 drug for a phase 2 clinical trial, targeting Clostridioides difficile infection, with the study expected to start in the first half of 2026 [9]. Radiopharm Theranostics Limited (NASDAQ:RADX) - Radiopharm Theranostics Limited is developing treatments for conditions such as brain metastasis and prostate cancer [10]. - B. Riley lowered its price target for Radiopharm to $13 from $15 while maintaining a Buy rating, citing important clinical progress for its RAD 101 and RAD 204 compounds [10]. - RAD 204's phase 1 clinical trial showed promising results, and RAD 101 is currently in a Phase 2b trial with FDA Fast Track Designation, targeting a market of 300,000 annual diagnoses of cerebral metastases in the US [11].

Core Insights - Radiopharm Theranostics is advancing its clinical programs with promising early data from multiple trials, indicating strong potential for its radiopharmaceutical pipeline [1][2][3] Clinical Trials and Data - Preliminary data from the Phase 2b trial of RAD 101 shows uptake in brain metastases from solid tumors, with topline results expected by H1 2026 [1][6] - The Phase 1 trial of RAD 202 (HER2) has shown higher than expected tumor uptake, with data from the second cohort anticipated by year-end 2025 [1][10] - RAD 204 (PD-L1) has demonstrated promising tumor uptake and stable disease in two out of three patients at the first dose level [5][11] - RAD 301 is being evaluated in a Phase 1 imaging trial for pancreatic cancer, with initial data supporting a move to a Phase 2 trial [8][12] Regulatory and Designation Updates - RAD 101 has received FDA Fast Track Designation to expedite its review process for patients with cerebral metastases [3] - RAD 301 has received Orphan Drug Designation from the FDA, highlighting its potential in treating pancreatic ductal adenocarcinoma [8] Company Strategy and Future Plans - The company plans to initiate Phase 1 trials for RV01 and RAD402 by year-end 2025, expanding its clinical portfolio to include four therapeutic candidates and two imaging agents [2] - The strategic execution of the company remains strong, with a focus on advancing multiple trials and achieving significant milestones [2][9]